Pharma Industry

More than half of the nation’s state top lawyers pen letter to leaders in House and Senate.

Change takes effect in 2025 and could benefit more than one million Medicare beneficiaries

PhRMA, U.S. Chamber warn of unintended consequences, market effects of negotiations.

Administration, HHS tout milestone day on road to lowering drug prices for beneficiaries.

It's time for pharmaceutical companies and others to innovate and disrupt the distribution side of treatment.

Prescription drug prices, vaccine costs are also key issues.

In 2024, beneficiaries could see savings per dose, according to new guidance on price increases relative to inflation.

Public-private partnerships will crumble, hurting drug innovation and eventually patients, Republicans say.